Glenmark Settles Litigation with Daiichi Sankyo, Genzyme over Welchol (Colesevelam Hydrochloride)
- Sterne, Kessler, Goldstein & Fox P.L.L.C.
Glenmark Pharmaceuticals successfully settled its litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) for Welchol® (Colesevelam Hydrochloride), a drug used in treatment of type-2 diabetes. As a result of the settlement, Glenmark has received a license from Daiichi Sankyo and Genzyme that will permit Glenmark to launch its generic Colesevelam Hydrochloride products on April 02, 2015 or earlier under certain circumstances.
The Sterne Kessler litigation team that successfully represented Glenmark in this matter included H. Keeto Sabharwal, Daniel E. Yonan, and Jeremiah B. Frueauf.
Read the full press release at Business Standard.
Download the attached PDF to read the decision.